Kreitman Robert J, Pastan Ira
Clinical Immunotherapy Section, Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 37, Room 5124b, Bethesda, MD 20892-4255, USA.
Hematol Oncol Clin North Am. 2006 Oct;20(5):1137-51, viii. doi: 10.1016/j.hoc.2006.06.009.
An increasing number of patients who have hairy cell leukemia (HCL) have persistent disease that requires treatment, despite purine analogs, splenectomy, interferon, and rituximab. Many of these patients have been treated successfully with immunotoxins. An immunotoxin contains a protein toxin connected to a cell-binding ligand, such as an antibody. An immunotoxin recognizes the target cell, internalizes, and the toxin translocates to the cytosol where it inhibits protein synthesis enzymatically. Immunotoxins that show activity in HCL contain truncated Psedomonas exotoxin fused to the Fv fragments of anti-CD25 or anti-CD22 monoclonal antibodies. Both agents, termed LMB-2 and BL22, respectively, have been tested in patients who have HCL after failure of purine analogs and other therapies; major responses have been achieved in most patients.
尽管使用了嘌呤类似物、脾切除术、干扰素和利妥昔单抗，但患有毛细胞白血病（HCL）的患者中，需要治疗的持续性疾病患者数量仍在增加。这些患者中有许多已成功接受免疫毒素治疗。免疫毒素包含与细胞结合配体（如抗体）相连的蛋白质毒素。免疫毒素识别靶细胞，内化，然后毒素转移到细胞质中，在那里它通过酶促作用抑制蛋白质合成。在HCL中显示活性的免疫毒素包含与抗CD25或抗CD22单克隆抗体的Fv片段融合的截短型假单胞菌外毒素。这两种药物分别称为LMB-2和BL22，已在嘌呤类似物和其他疗法失败后的HCL患者中进行了测试；大多数患者都取得了主要反应。
